Brief: NeuroBo Pharma And Dong-A ST Partner To License And Develop Dong-A's Cardio-Metabolic Therapies

Dong-A ST

15/09/2022 13:55

Sept 15 (Reuters) - NeuroBo Pharmaceuticals Inc  NRBO.O :
    * NEUROBO PHARMACEUTICALS, INC. AND DONG-A ST CO. LTD.
ANNOUNCE
STRATEGIC COLLABORATION TO LICENSE AND DEVELOP PORTFOLIO OF
DONG-A'S CARDIO-METABOLIC THERAPIES
    * NEUROBO - LICENSE AGREEMENT TO DEVELOP & COMMERCIALIZE
PHASE II
CLINICAL STAGE NEW CHEMICAL ENTITY DA-1241 FOR TREATMENT OF NASH
/ TYPE 2 DIABETES
    * NEUROBO PHARMACEUTICALS INC - DONG-A COMMITS $15 MILLION
IN
EQUITY TO STRATEGIC COLLABORATION
    * NEUROBO PHARMACEUTICALS INC - LICENSE AGREEMENT TO DEVELOP
AND
COMMERCIALIZE PHASE I READY DA-1726 FOR TREATMENT OF NASH /
OBESITY
    * NEUROBO PHARMACEUTICALS - UNDER TERMS OF LICENSE
AGREEMENT,
DONG-A WILL RECEIVE AN UPFRONT PAYMENT OF $22 MILLION IN SERIES
A CONVERTIBLE PREFERRED STOCK
    * NEUROBO PHARMACEUTICALS INC - DONG-A WILL ALSO BE ENTITLED
TO
SINGLE DIGIT ROYALTIES ON NET SALES OF TWO ASSETS

Source text for Eikon:  ID:nPn8tQlbta 
Further company coverage:  NRBO.O 

 ((Reuters.Briefs@thomsonreuters.com;))